Analysts Update Price Targets and Ratings for Xencor
Multiple financial institutions, including Wells Fargo, RBC Capital Markets, and Wedbush, updated their ratings and price targets for Xencor on November 2, 2026.
Stocks · News reference
Xencor, Inc. Reports Q3 2026 Financial Results
Xencor, Inc. announced its third-quarter 2026 financial results, reporting revenue of $116.5 million and earnings per share of $0.50, both significantly exceeding analyst expectations.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wells Fargo and Barclays Adjust Price Targets for Xencor
Wells Fargo and Barclays have both updated their price targets for Xencor, Inc. following recent clinical updates.
Analysts Raise Price Targets on Xencor
RBC Capital Markets and Wedbush have both increased their price targets for Xencor, maintaining their positive outlooks on the company.
Wedbush Maintains Outperform on Xencor, Raises Price Target to $45
Wedbush Adjusts Xencor Price Target to $45
Wedbush Securities updated its price target for Xencor, Inc. to $45 from $30 while maintaining an Outperform rating.
Xencor Drug Shows Unprecedented Profile in Colorectal Cancer: Analyst
Xencor reports upbeat Phase 1 kidney cancer data for XmAb819 at ESMO 2026 and selects 400 mcg/kg as the primary proposed Phase 3 study dose.